scholarly journals Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report

2019 ◽  
Vol 8 (2) ◽  
pp. 693-698
Author(s):  
Shuchun Li ◽  
Junjun Ma ◽  
Xizhou Hong ◽  
Minhua Zheng ◽  
Shigenori Goto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Combination Therapy ◽  
Clinical Response ◽  
Advanced Colorectal Cancer ◽  
Adoptive Cell Transfer ◽  
Cell Transfer ◽  
Adoptive Cell Transfer Therapy

scholarly journals Adoptive-cell-transfer therapy for the treatment of patients with cancer

2003 ◽  
Vol 3 (9) ◽  
pp. 666-675 ◽  
Author(s):  
Mark E. Dudley ◽  
Steven A. Rosenberg
Keyword(s):  
Adoptive Cell Transfer ◽  
Cell Transfer ◽  
Patients With Cancer ◽  
Adoptive Cell Transfer Therapy

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

2010 ◽  
Vol 66 (5) ◽  
pp. 987-992 ◽  
Author(s):  
Manabu Shiozawa ◽  
Makoto Akaike ◽  
Nobuhiro Sugano ◽  
Kazuhito Tsuchida ◽  
Naoto Yamamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Combination Therapy ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study

Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer

2003 ◽  
Vol 52 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Tadamichi Denda ◽  
Tomonori Ambo ◽  
Atsushi Ohtsu ◽  
Yasuhide Yamada ◽  
Kuniaki Shirao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Combination Therapy ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study

Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13553-13553
Author(s):  
W. A. Messersmith ◽  
M. A. Rudek ◽  
D. Laheru ◽  
M. Zhao ◽  
P. He ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Combination Therapy ◽  
Phase I ◽  
Dose Level ◽  
Dose Escalation ◽  
Advanced Colorectal Cancer ◽  
Standard Of Care ◽  
Maximum Tolerated Dose ◽  
Total Daily Dose ◽  
Dose Escalation Study

13553 Background: ABT-751 (A) is an orally (PO) bioavailable sulfonamide with antimitotic properties. We are performing a non-randomized phase I/II dose-escalation study of A in combination with capecitabine (C), irinotecan (I) and bevacizumab (B) to define the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) in patients with advanced colorectal cancer (1st or 2nd line). Methods: Patients are treated with A QD for 7d (lead-in) and then begin 21-d cycles of treatment with A (QD) and C (BID) d1–14 PO, I d1 IV, and B d1 IV. Dose escalation started at dose level (DL) 1 at A 150 mg, I 200 mg/m2, and C 1600 mg/m2 (total daily dose) and escalated to full dose CAPIRI (I 250 mg/m2, and C 2000 mg/m2) for DL2. B was then added as standard of care at 7.5 mg/kg for DL2b (and later, DL1b). Blood samples were collected for pharmacogenomics (PG), pharmacodynamics (PD), steady-state PK of A and A metabolites when administered alone or in combination with C, I, and B, and PK of I and I metabolites. Serial dynamic contrast MRI’s, before and after the ABT-751 monotherapy lead-in period, are being performed in a subset of subjects. Results: Eight patients have been treated at dose levels 1 (3), 2 (2), and 2b (3). One patient on DL2 experienced g3 transaminitis and another on DL2b had F&N which were dose-limiting. Dose level 1 is being expanded to 6 patients, now with B (DL1b). Other g3/4 toxicities have included g4 neutropenia (1 subject DL2, 1 DL2b). The formation of A glucuronide appears decreased during combination therapy (see table). I PK, PD, and PG samples were collected and analysis is pending. Of 8 subjects, there have been 4 PD and 4 SD after 2 cycles. Conclusions: The combination therapy of A 150 mg and 20% dose-reduced CAPIRI appears well-tolerated. Patient accrual continues at DL1b. [Table: see text] No significant financial relationships to disclose.

Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group study HGCSG-0302)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3589-3589
Author(s):  
Y. Komatsu ◽  
S. Yuki ◽  
H. Akita ◽  
M. Kudo ◽  
M. Tateyama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Study ◽  
Combination Therapy ◽  
Survival Time ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Response Rate ◽  
Dose Intensity ◽  
Outpatient Basis ◽  
Phase Ii Clinical Study

3589 Background: We planned to conduct a phase II clinical study of combination therapy with irinotecan and S-1, a new oral anticancer drug of the fluorinated pyrimidine type. We reported the interium reports of this study in colorectal cancer patients at GI cancer Symposium 2006. Methods: The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and median survival time were the secondary endpoints. The subjects were untreated patients with inoperable advanced colorectal cancer aged 20–75 years. Irinotecan was administered at a dose of 100 mg/m2 (on days 1 and 15) as an intravenous infusion over 90 minutes, and oral S-1 (40 mg/m2) was administered after breakfast and dinner and then withdrawn for 2 weeks. Results: Forty patients were enrolled in the present study. There were 23 men and 17 women. The median age was 62 years (range: 34 to 74 years). Two patient showed grade 4 neutropenia, but the next course could be given safely after dose reduction. Three patients had grade 3 diarrhea, but therapy could be continued with addition of an antidiarrheal drug. No other serious adverse reactions occurred (either hematological or non-hematological), and all patients could receive therapy safely on an outpatient basis. Interim analysis suggested excellent results, with a response rate of 50%. To date, 231 cycles (median 8, range 1–19) have been administered. Median relative dose intensity was 97% for S-1 and 87% for irinotecan. 36 pts are evaluable for efficacy: RR was 47.2% (95% CI, 30.9–63.5%) and Disease Control Rate (PR + SD) was seen in 94.4% of pts. PFS of this regimen is 320 days. MST is not reached. Conclusions: IRIS therapy achieved a high response rate and could be given safely. These findings suggest that the therapy has potential as first-line treatment for inoperable advanced recurrent colorectal cancer. It seems that IRIS is a good treatment equal to FOLFIRI. In addition, this regimen could qualify as a candidate for future combination therapy with a molecular-targeting drug. The latest data will be reported at the meeting. No significant financial relationships to disclose.

scholarly journals Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor

2012 ◽  
Vol 10 (1) ◽  
pp. 69 ◽  
Author(s):  
Robert PT Somerville ◽  
Laura Devillier ◽  
Maria R Parkhurst ◽  
Steven A Rosenberg ◽  
Mark E Dudley
Keyword(s):  
Adoptive Cell Transfer ◽  
Rapid Expansion ◽  
Cell Transfer ◽  
Clinical Scale ◽  
Adoptive Cell Transfer Therapy
Sign in / Sign up

Export Citation Format

Share Document